Cipla, the largest player in the domestic drug market, could play white knight for Cipla Medpro, South Africa's third-largest drugmaker and a key ally of the Indian company. Cipla is looking to acquire around 25 per cent in the manufacturing division of Cipla Medpro, where it does not hold any stake at present.
The Hyderabad-based drugmaker said consolidated net profit rose to Rs Rs 361 crore (Rs 3.61 billion) for the fiscal first quarter ended June, from Rs 336 crore (Rs 3.36 billion) a year earlier.
India's pharma companies are moving beyond generics to set their sights on the research and development of new drugs, but the risks are many
The initiative will include special training for Customs and drug regulatory officials to identify spurious drugs, their origin, distribution chain and follow-up action to raid premises and book culprits, in coordination with regulatory and police officials of various countries.
Daiichi-Sankyo's $5.3 billion acquisition of India's biggest drugmaker will help the Japanese company compete in the US markets with rivals such as Mylan and Israel-based Teva Pharmaceuticals and climb to become the world's 15th largest pharmaceutical company. Thus it is an important move on the part of an original drug research company to attach generic business portfolio," noted Ranjit Shahani, the vice-chairman and managing director of Novartis India.
The USTR has placed India on its "priority watch" list for two years in a row, saying the country's patent laws unfairly favour local drug makers.
Its factory in Chikalthana in western India was last month hit by the British drug regulator's curb on imports from the plant over manufacturing deficiencies.
In its ongoing patent litigation over cholesterol lowering drug atorvastatin (Lipitor) against India's Ranbaxy Laboratories, Pfizer said on Tuesday in a court in Ireland had ruled in its favour.
Both companies can now complete the deal.
Sun Pharma has increased its stake in Israel's Taro by buying 9.5% more, raising its total holding to 34.4 per cent.
Japan's Daiichi Sankyo makes Ranbaxy Laboratories an offer it can't refuse -- $4.6 billion for a 50.1% stake in India's largest drugmaker.
As India's largest drugmaker unveiled a deal worth up to $4.6bn to sell control to Daiichi Sankyo of Japan, the disbelief at the press conference was palpable.
The transaction, to be followed up by an open offer, puts the entire deal value between $3.4 billion and $4.6 billion.
The health ministry on Saturday recommended the use of antiviral drug remdesivir in moderate stage of COVID-19 while backtracking from its earlier stance on hydroxychloroquine, saying the anti-malarial drug should be used in the early course of the disease and not on critically ill patients.
AstraZeneca Plc and the University of Oxford are facing questions about their Covid-19 vaccine and whether regulators would quickly authorise its emergency use after the pharma company acknowledged an error in the vaccine dosage received by some participants and other irregularities and omissions, according to the New York Times.
Ranbaxy Laboratories, India's biggest drugmaker, may lose as much as $140 million of revenue in 2009 after the US drug regulator blocked sale of more than 30 generic medicines and 7 APIs made in two factories of the company, according to analysts.
However, in two different dose regimens, the vaccine's efficacy was 90 per cent in one and 62 per cent in the other.
The drugmaker has enjoyed big success with low-cost alternatives to AIDS and other high-priced drugs. But NGOs are taking away sales.
Pfizer and BioNTech said they have concluded phase 3 study of their mRNA-based COVID-19 vaccine candidate BNT162b2, meeting all primary efficacy endpoints.
Drugmaker Lupin Ltd said on Monday it has signed a licensing agreement with leading Italian pharmaceutical company ItalFarmaco for marketing its cardiovascular critical care product in the Indian market.
Ranbaxy Laboratories, the country's biggest drugmaker by sales, said on Tuesday it would set up a research and development facility in North America.\n\n\n\n
Ranbaxy Laboratories, the country's biggest drugmaker, is all set to focus its energies in developing and marketing niche products where price erosion is minimal
In another setback to India's biggest drugmaker Ranbaxy Laboratories Ltd, a court in Finland has prohibited it from marketing its generic version of Pfizer's cholesterol lowering drug Lipitor in the country.
In a boost to India's biggest drugmaker Ranbaxy Laboratories Ltd, an Austrian panel has ruled in the company's favour in a patent litigation against Pfizer involving cholesterol lowering drug 'Lipitor' in that country.
Tata Motors and drugmaker Ranbaxy are among the seven Indian firms in the world's top 1,250 companies ranked on the basis of investments in research and development. According to a study by the UK government, the world's top 1,250 R&D investment companies together spent 244 billion pounds ($507 billion) in 2006, up 10 per cent from the previous year.
Jhunjhunwala increases stake in DHFL, luggage maker VIP Industries and pharma major Lupin but is cautious on auto holding. At the end of the March quarter, Jhunjhunwala held positions in 29 firms.
India's biggest drugmaker Ranbaxy Laboratories Ltd, which has decided to put its manufacturing unit in Ireland on the block, may sell it for 25-35 million Euros. \n\n
On December 4 last year, the stock of the world's largest drugmaker, Pfizer, fell 10.6 per cent, wiping out more than $21 billion in market value in a single day.
India's biggest drugmaker Ranbaxy on Thursday acquired the 10th largest generic company in Belgium, Ethimed NV, for an undisclosed sum, a day after it shelled out $324 million to buy Terapia in Romania.
GSK is continuing with investigations into the potential source of the NDMA, which is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.
The shares of Ranbaxy Laboratories fell 3.3 per cent on the bourses on Wednesday amid speculation the promoters of the country's top drugmaker were planning to dilute their stake, but the company denied any such move.
Several companies, including Indian units of Abbott Laboratories and Pfizer Inc, and domestic firms like Cipla Ltd and Macleods Pharmaceuticals, went to the Delhi High Court to try to get the ban lifted.
Indian drugmaker Morepen Laboratories Ltd has filed an international patent for the manufacturing process of Desloratadine, the Bombay Stock Exchange said on Wednesday.
GlaxoSmithKline plc, Europe's biggest drugmaker, said on Wednesday that it was accelerating work on a possible vaccine against the deadly SARS virus but warned development would take years.
Domestic pharma giant Ranbaxy Laboratories Limited has topped the list of patent filers in the area of drug applications from the Third World countries last year with 64 new formulations.\n\n\n\n
Ranbaxy Laboratories Ltd, India's top drugmaker by sales, said it expected to get US approvals for a paediatric dosage of its generic version of Augmentin, GlaxoSmithKline's blockbuster antibiotic, within a month.\n\n\n\n
Swedish firm Astra Pharmaceutical will buy out the remaining less than 10 per cent stake in its local arm Astrazeneca Pharma India by next year following approval from the Foreign Investment Promotion Board.
Drugmaker major Wockhardt plans to introduce two new products - recombinant Human Insulin and Interferon alpha 2b - in the domestic market next year.
US District Judge Beryl Howell in Minneapolis denied Ranbaxy's request, the court filing showed.
Indian drugmaker Dr Reddy's Laboratories Ltd said on Wednesday it has filed with the US Food and Drug Administration to market a generic version of Aventis Pharmaceuticals' anti-allergy drug Allegra.
